Gw pharmaceuticals gwph stock price

View today's stock price, news and analysis for GW Pharmaceuticals PLC ADR (GWPH). Barron's also provides information on historical stock ratings, … GW Pharmaceuticals Plc (GWPH) stock price, quote, history ... GW Pharmaceuticals plc (GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with its U.S. subsidiary Greenwich Biosciences, Inc., today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with Priority

Cookie Notification. We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's  Nov 27, 2019 GW Pharmaceuticals (NASDAQ: GWPH) is a biopharmaceutical This price decline follows the overall weakness in cannabis stocks over  Nov 26, 2019 GW Pharmaceuticals (GWPH) is a biopharmaceutical company This price decline follows the overall weakness in cannabis stocks over  Oct 7, 2019 Nine analysts covered the stock in October 2018. The consensus target price for GWPH is down to $226.85 this month from $227.31 in  Stockopedia rates GW Pharmaceuticals as a Adventurous Style Neutral . 10 brokers rate it as a 'Buy'. Click to view NMQ:GWPH's StockReport. StockRank™ . Learn about GWPH with our data and independent analysis including price, star rating, valuation, dividends, and Stocks by Morningstar Classification 

Get today's GW Pharmaceuticals PLC ADR stock price and latest GWPH news as well as GW Pharma ADR real-time stock quotes, technical analysis, full 

GWPH Stock Summary. With a price/sales ratio of 8.69, Gw Pharmaceuticals Plc has a higher such ratio than 90.56% of stocks in our set. With a year-over-year  Get today's GW Pharmaceuticals PLC ADR stock price and latest GWPH news as well as GW Pharma ADR real-time stock quotes, technical analysis, full  View today's stock price, news and analysis for GW Pharmaceuticals PLC ADR ( GWPH). Barron's also provides information on historical stock ratings, target  Historical daily share price chart and data for GW Pharmaceuticals since 2020 adjusted for splits. The latest closing stock price for GW Pharmaceuticals as of  GW Pharmaceuticals stock price, live market quote, shares value, historical data, intraday chart, earnings per share and news.

GW Pharmaceuticals PLC Sponsored ADR - TheStreet

View live GW PHARMACEUTICALS ADS EA REPR 12 ORD GBP0.00 chart to track its stock's price action. Find market predictions, GWPH financials and market news. GWPH - Stock quote for GW PHARMACEUTICALS PLC - MSN Money View the latest GWPH stock quote and chart on MSN Money. Dive deeper with interactive charts and top stories of GW PHARMACEUTICALS PLC. GW Pharmaceuticals: Analysts’ Ratings, Price Target ... Nov 13, 2019 · GW Pharmaceuticals (GWPH) recently reported its QA3 results. Although its financials beat estimates, the company's stock has fallen 18% since then. GWPH GW Pharmaceuticals plc — Stock Price and Discussion ...

GW Pharmaceuticals plc (GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with its U.S. subsidiary Greenwich Biosciences, Inc., today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with Priority

GW Pharmaceuticals - GWPH - Stock Price & News | The ...

GW Pharmaceuticals PLC ADR analyst ratings, historical stock prices, earnings estimates & actuals. GWPH updated stock price target summary.

Jan 17, 2020 GW Pharmaceuticals PLC (GWPH) stocks rallied this week after the Ahmad held her Buy rating on GWPH with a $224 price objective. GW Pharmaceuticals Plc (GWPH) Stock Price, Quote, History ... Find the latest GW Pharmaceuticals Plc (GWPH) stock quote, history, news and other vital information to help you with your stock trading and investing. GW Pharmaceuticals - GWPH - Stock Price & News | The ...

GWPH Stock Quote - GW Pharmaceuticals Plc Stock Price Today GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It offers its cannabinoid product, Epidiolex oral solution CV, a pharmaceutical formulation of cannabidiol (CBD) focusing on the treatment of seizures associated with tuberous sclerosis complex.